Sanctuary Advisors LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 8,505 shares of the medical research company’s stock, valued at approximately $1,643,000.
Other large investors also recently made changes to their positions in the company. Financial Freedom LLC bought a new stake in IQVIA in the 1st quarter worth about $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA during the 1st quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth approximately $27,000. Compass Financial Management LLC bought a new position in shares of IQVIA in the second quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC bought a new position in shares of IQVIA in the fourth quarter valued at approximately $27,000. 89.62% of the stock is owned by institutional investors.
IQVIA Stock Up 0.8%
IQV stock opened at $261.57 on Thursday. The stock has a fifty day moving average of $218.41 and a 200-day moving average of $188.59. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $262.51. The company has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 2.22 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.
IQVIA declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Stifel Nicolaus upped their price objective on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Robert W. Baird lifted their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. HSBC reissued a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Royal Bank Of Canada lifted their price objective on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $241.88.
Insider Buying and Selling
In other news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company’s stock.
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Articles
- Five stocks we like better than IQVIA
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
